Jump to content

Milameline

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 86.23.68.198 (talk) at 22:24, 23 July 2014. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Milameline
Clinical data
ATC code
  • None
Identifiers
  • (E)-N-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.220.595 Edit this at Wikidata
Chemical and physical data
FormulaC8H14N2O
Molar mass154.21 g/mol g·mol−1
3D model (JSmol)
  • N(/OC)=C\C1=C\CCN(C)C1

Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.[1]

Synthesis

  1. Ester of arecoline is reduced with LAH.
  2. Swern oxidation to aldehyde.
  3. Analogous to brasofensine, methylaldoxime is formed by imine formation via condensation with methoxyamine.

See also

References

  1. ^ Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 877–82. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.{{cite journal}}: CS1 maint: multiple names: authors list (link)


Template:Nootropics

Retrieved from "https://en.wikipedia.org/w/index.php?title=Milameline&oldid=618184535"